Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids

van der Molen, T.; Postma, D. S.; Turner, M. O.; Meyboom-de Jong, B.; Malo, J. L.; Chapman, K.; Grossman, R.; de Graaf, C. S.; Riemersma, R. A.; Sears, M. R.
June 1997
Thorax;Jun1997, Vol. 52 Issue 6, p535
Academic Journal
No abstract available.


Related Articles

  • Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma: Commentary. Rees, P. John // Evidence Based Medicine;Aug2005, Vol. 10 Issue 4, p116 

    Focuses on the control of asthma by inhaled long acting beta agonists and corticosteroids. Effectiveness of the combination of fluticasone/salmeterol and budesonide/formoterol; Dose response of corticosteroids and formoterol; Onset of bronchodilation.

  • Clinical trials in asthma.  // Thorax;Dec2013 Supplement, Vol. 68 Issue S3, pA148 

    The article presents abstracts on topics related to Asthma clinical trials including controlled trial of Formoterol, beta agonist, inhaler as reliever therapy in asthma patients, effect of Propranolol in corticosteroid dose of asthma patients, and bronchodilator Tiotropium's effect in asthmatics.

  • Formoterol: An Update of its Pharmacological Properties and Therapeutic Efficacy in the Management of Asthma. Bartow, R.A.; Brogden, R.N. // Drugs;Feb1998, Vol. 55 Issue 2, p303 

    Formoterol, a selective β2-adrenoceptor agonist, produces effective dose-proportional bronchodilation, which persists for up to 12 hours, in patients with reversible obstructive respiratory disease. Bronchodilation is significant within minutes of inhalation, maximal within 2 hours, and at...

  • A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease. Sovani, Milind P; Whale, Christopher I.; Tattersfield, Anne. E // Drug Safety;2004, Vol. 27 Issue 10, p689 

    The two inhaled long-acting β2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease...

  • Beclomethasone revisited: the modern view of a classic inhaled corticosteroid. Bakakos, Petros; Loukides, Stelios; Kostikas, Konstantinos // Pneumon;Apr-Jun2014, Vol. 27 Issue 2, p120 

    Asthma is a worldwide problem affecting more than 300 million people of all ages with a relevant impact on quality of life and healthcare resources. International guidelines recommend the combination of a long acting beta-2-agonist and an inhaled corticosteroid when asthma is not fully...

  • MHRA to review the safety and use of LABAs.  // GP: General Practitioner;3/2/2007, p4 

    The article reports that the Medicines and Healthcare Products Regulatory Agency (MHRA) of Great Britain is reviewing the use of the long-acting beta-2 agonists (LABAs) formoterol and salmeterol in the treatment of asthma and COPD patients. Understanding how corticosteroid inhalers can influence...

  • Budesonide and Formoterol Reduce Early Innate Anti- Viral Immune Responses In Vitro. Davies, Janet M.; Carroll, Melanie L.; Hongzhuo Li; Poh, Alisa M.; Kirkegard, Darren; Towers, Michelle; Upham, John W. // PLoS ONE;2011, Vol. 6 Issue 11, p1 

    Asthma is a chronic inflammatory airways disease in which respiratory viral infections frequently trigger exacerbations. Current treatment of asthma with combinations of inhaled corticosteroids and long acting beta2 agonists improves asthma control and reduces exacerbations but what impact this...

  • Long-Acting β-Agonist Treatment in Patients with Persistent Asthma Already Receiving Inhaled Corticosteroids. Hancox, R.J.; Taylor, D.R. // BioDrugs;2001, Vol. 15 Issue 1, p11 

    International guidelines recommend that long-acting β-agonists should be considered in patients who are symptomatic despite moderate doses of inhaled corticosteroids. When combined with inhaled corticosteroids they improve asthma symptoms and lung function and reduce exacerbations. The...

  • Budesonide/Formoterol: A Review of its Use as Maintenance and Reliever Inhalation Therapy in Asthma. McCormack, Paul L.; Lyseng-Williamson, Katherine A. // Drugs;2007, Vol. 67 Issue 16, p2407 

    The use of combination budesonide/formoterol dry powder inhaler (Symbicort® Turbuhaler®) for both daily maintenance therapy and as-needed relief of breakthrough symptoms using a single inhaler is a new approach to asthma management that is indicated in patients with persistent asthma not...

  • Medical Therapy for Asthma: Updates from the NAEPP Guidelines. ELWARD, KURTIS S.; POLLART, SUSAN M. // American Family Physician;2015 Special Issue, Vol. 91, p1 

    Proper care of patients with asthma involves the triad of systematic chronic care plans, self-management support, and appropriate medical therapy. Controller medications (inhaled corticosteroids, long-acting beta2 agonists, and leukotriene receptor antagonists) are the foundation of care for...


Read the Article


Sign out of this library

Other Topics